Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Abstract

Background and purpose: The aim of the Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke.

Methods: Preliminary work was performed by seven working groups of stroke leaders followed by a synergium (a forum for working synergistically together) with approximately 100 additional participants. The resulting draft document had further input from contributors outside the synergium.

Results: Recommendations of the Synergium are: Basic Science, Drug Development and Technology: There is a need to develop: (1) New systems of working together to break down the prevalent 'silo' mentality; (2) New models of vertically integrated basic, clinical, and epidemiological disciplines; and (3) Efficient methods of identifying other relevant areas of science. Stroke Prevention: (1) Establish a global chronic disease prevention initiative with stroke as a major focus. (2) Recognize not only abrupt clinical stroke, but subtle subclinical stroke, the commonest type of cerebrovascular disease, leading to impairments of executive function. (3) Develop, implement and evaluate a population approach for stroke prevention. (4) Develop public health communication strategies using traditional and novel (eg, social media/marketing) techniques. Acute Stroke Management: Continue the establishment of stroke centers, stroke units, regional systems of emergency stroke care and telestroke networks. Brain Recovery and Rehabilitation: (1) Translate best neuroscience, including animal and human studies, into poststroke recovery research and clinical care. (2) Standardize poststroke rehabilitation based on best evidence. (3) Develop consensus on, then implementation of, standardized clinical and surrogate assessments. (4) Carry out rigorous clinical research to advance stroke recovery. Into the 21st Century: Web, Technology and Communications: (1) Work toward global unrestricted access to stroke-related information. (2) Build centralized electronic archives and registries. Foster Cooperation Among Stakeholders (large stroke organizations, nongovernmental organizations, governments, patient organizations and industry) to enhance stroke care. Educate and energize professionals, patients, the public and policy makers by using a 'Brain Health' concept that enables promotion of preventive measures.

Conclusions: To accelerate progress in stroke, we must reach beyond the current status scientifically, conceptually, and pragmatically. Advances can be made not only by doing, but ceasing to do. Significant savings in time, money, and effort could result from discontinuing practices driven by unsubstantiated opinion, unproven approaches, and financial gain. Systematic integration of knowledge into programs coupled with careful evaluation can speed the pace of progress.

PubMed Disclaimer

Conflict of interest statement

Disclosures

G.A.D.a received other research support from Boehringer Ingelheim (BI) and Sanofi-Aventis; Consultant/Advisory Board for BI, Servier, Sanofi-Aventis, Bristol Myer Squibb. P.B.G. received Speakers Honoraria from BI; Consultant/Advisory Board for Bayer, Abott, Takeda.S.C.C.d, h received research grant from GlaxoSmith-Kline (GSK) and Stem Cell Therapeutics; Consultant/Advisory Board for GSK, Stem Cell Therapeutics, Johnson and Johnson, Photothera (all significant) and Pfizer Inc, Allergan Inc, Grupo Ferrer SA (all modest). M.K.e,h received Honoraria from BI, PAION AG, Servier, Forest Research Laboratories Inc, Neurobiological Technologies Inc, and Lund beck AS for participating in the Steering Committee meetings of ProFESS, PERFORM, ANCROD, and all ECASS, DIAS and CEPO trials, and for giving lectures in national and international meetings sponsored by the above mentioned companies and Sanofi-Aventis and BMS; Consultant/Advisory Board for BI, PAION AG,Servier, Forest Research Laboratories Inc, Neurobiological Technologies Inc, and Lund beck AS.B.E.S.a is an employee of Novo Nordisk. K.L.F.b received IRIS trial funding through National Institute of Neurological Disorders and Stroke (NINDS). G.J.H.b received Speakers Honoraria from Pfizer, Sanofi-Aventis; Consultant/Advisory Board for BI, Sanofi-Aventis. J.C.M. b participated/is currently participating in clinical trials of antidementia drugs sponsored by Elan, Eli Lilly and Company, Wyeth; Consultant/ Speaking Honoraria from AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, Merck, Novartis, Pfizer, Schering Plough, Wyeth Elan. R.L.S.b received a research grant from NINDS (Northern Manhattan Stroke Study). Y.W.b is CEO and serves as/on Consultant/Advisory Board of InTouch Health, Goleta, Calif. G.A.F. c: payment to institution from companies undertaking stroke research including Lund beck, Mitsubishi, PAION, BI for trial related activities; payment to institution for administrative support of UK SITS database, BI; personal payment for educational lectures (modest) and advisory board (modest), BI, Lund beck. S.C.O.M.c received lecture fees from BI.J.S.c is employed at University of California; received research grants from National Institutes of Health (NIH); Consultant/Advisory Board of Talacris, Syquil, EV3, AGA, Brainsbok; University of California receives research grants from NIH and hundreds of industry companies; University of California has patent interest in the Merci retriever. M.M.B. d is an employee of Pfizer Inc. P. D. d is an employee of Duke University. L.E.d is an employee of GSK.S.F.d is an employee of Biotrofix, Inc and Massachusetts General Hospital (significant); has ownership interest in Biotrofix, Inc; and Consultant/Advisory Board for Pfizer, GSK, Johnson and Johnson, Acorda, and Lanthers. J.K. d is employed at University of Florida. L.H.S.e, Consultant/Advisory Board for Massachusetts Department of Public Health and Phreesia Inc. B.T.e is employed at Southern IL Healthcare. N.W.e is employed at Karolinska Institute. L.K.W.e is employed at Chinese University of Hong Kong. S.P.f is employed at the American Heart Association. V.H.,W.H. c,h,M.F.f,h, M.B.g,h,A M B a, E.H.L.a, P.M.R.b, S.C.S.b, A.B.c, C.I.c, M.B.d, T.A.J.d, L.K. d, R.N. d, R.T.d, C.W.d, M.P.G.e, W.-D.H. e,O. S. e, Y.S.e, A.H.f, B.N.f, N.M.B.g,S.M.D.g,L.B.G.g,D.L.g,J.T.g,M.K.b,V.S.c,and B.D.e have no conflicts to report.

Figures

Fig. 1
Fig. 1
Source: Internet world stats. Available at: www.internetworldstats.com/ stats.htm. Penetration rates are based on a world population of 6,767,805,208 and 1,733,993,741 estimated Internet users for September 30, 2009. Copyright 2009, Miniwatts Marketing Group.

Similar articles

  • Stroke: working toward a prioritized world agenda.
    Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, Fisher M, Brainin M, Buchan AM, Lo EH, Skolnick BE, Furie KL, Hankey GJ, Kivipelto M, Morris J, Rothwell PM, Sacco RL, Smith SC Jr, Wang Y, Bryer A, Ford GA, Iadecola C, Martins SC, Saver J, Skvortsova V, Bayley M, Bednar MM, Duncan P, Enney L, Finklestein S, Jones TA, Kalra L, Kleim J, Nitkin R, Teasell R, Weiller C, Desai B, Goldberg MP, Heiss WD, Saarelma O, Schwamm LH, Shinohara Y, Trivedi B, Wahlgren N, Wong LK, Hakim A, Norrving B, Prudhomme S, Bornstein NM, Davis SM, Goldstein LB, Leys D, Tuomilehto J. Hachinski V, et al. Stroke. 2010 Jun;41(6):1084-99. doi: 10.1161/STROKEAHA.110.586156. Stroke. 2010. PMID: 20498453 Free PMC article. Review.
  • Stroke: working toward a prioritized world agenda.
    Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, Fisher M, Brainin M, Buchan AM, Lo EH, Skolnick BE, Furie KL, Hankey GJ, Kivipelto M, Morris J, Rothwell PM, Sacco RL, Smith SC Jr, Wang Y, Bryer A, Ford GA, Iadecola C, Martins SC, Saver J, Skvortsova V, Bayley M, Bednar MM, Duncan P, Enney L, Finklestein S, Jones TA, Kalra L, Kleim J, Nitkin R, Teasell R, Weiller C, Desai B, Goldberg MP, Heiss WD, Saarelma O, Schwamm LH, Shinohara Y, Trivedi B, Wahlgren N, Wong LK, Hakim A, Norrving B, Prudhomme S, Bornstein NM, Davis SM, Goldstein LB, Leys D, Tuomilehto J; Stroke Synergium. Hachinski V, et al. Cerebrovasc Dis. 2010;30(2):127-47. doi: 10.1159/000315099. Epub 2010 May 24. Cerebrovasc Dis. 2010. PMID: 20516682 Free PMC article.
  • The future of Cochrane Neonatal.
    Soll RF, Ovelman C, McGuire W. Soll RF, et al. Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
  • How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D, Rixson L. Allen D, et al. Int J Evid Based Healthc. 2008 Mar;6(1):78-110. doi: 10.1111/j.1744-1609.2007.00098.x. Int J Evid Based Healthc. 2008. PMID: 21631815
  • Critical Care Network in the State of Qatar.
    Hijjeh M, Al Shaikh L, Alinier G, Selwood D, Malmstrom F, Hassan IF. Hijjeh M, et al. Qatar Med J. 2019 Nov 7;2019(2):2. doi: 10.5339/qmj.2019.qccc.2. eCollection 2019. Qatar Med J. 2019. PMID: 31763205 Free PMC article.

Cited by

References

    1. Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke.The Framingham study. JAMA. 1970;12:301–310. 214. - PubMed
    1. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299:53–59. - PubMed
    1. Norris JW, Hachinski VC. Intensive care management of stroke patients. Stroke. 1976;7:573–577. - PubMed
    1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med. 1995;333:1581–1587. - PubMed
    1. Millikan CH. Stroke: 970–1977. Stroke. 2001;32:3–5. - PubMed

Publication types